Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042859 | 0.89 | USP2 (0.50) | USP2TSHRMAPK1HIF1AKDM4E | |
| SCHEMBL14282215 | 0.89 | MAPK1 (0.64) | TSHRMAPK1HIF1AKDM4EADRB2 | |
| SCHEMBL772782 | 0.85 | USP2 (0.54) | USP2TSHRMAPK1HIF1AKDM4E | |
| SCHEMBL1496742 | 0.83 | ADRB2 (0.66) | TSHRMAPK1HIF1AADRB2ADRB1 | |
| SCHEMBL13572916 | 0.83 | TSHR (0.76) | TSHRMAPK1HIF1AKDM4ETP53 | |
| SCHEMBL8508885 | 0.81 | CASR (0.52) | TSHRMAPK1HIF1AKDM4EKMT2A | |
| SCHEMBL14027336 | 0.81 | ALDH1A1 (0.54) | TSHRMAPK1HIF1AKDM4EADRB2 | |
| SCHEMBL14218171 | 0.81 | CASR (0.52) | TSHRMAPK1HIF1AKDM4EKMT2A | |
| SCHEMBL4334251 | 0.81 | CYP3A4 (0.61) | TSHRMAPK1HIF1AKDM4EADRB2 | |
| SCHEMBL4653976 | 0.81 | USP2 (0.51) | USP2TSHRMAPK1HIF1AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723136-B1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-06-19 | — | — | US | disclosed |
| US-7355051-B2 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2008-04-08 | — | — | US | disclosed |
| US-7355051-B2 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2008-04-08 | — | — | US | disclosed |
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-04-26 | — | — | US | disclosed |
| WO-2005058873-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | NQO2, NOX1, NOX3 | USP2 2226/4885TSHR 1493/4885MAPK1 3664/4885 |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | NQO2, NOX3, NOX1 | USP2 2397/4885TSHR 1679/4885MAPK1 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.